Latigo Biotherapeutics (NASDAQ:LTGO) Stock Price & Analysis

–

USD

–(–)

Company Profile

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

CEONima Farzan

SectorHealthcare

IndustryMedical - Pharmaceuticals

Employees59

IPO DateAug 7, 2026

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

Address1300 Rancho Conejo Boulevard, Suite 305

City / State / ZIPThousand Oak, CA, 91320

CountryUnited States

Websitehttp://www.latigobio.com

Latigo Biotherapeutics Inc.

Company Profile

Recently from Cashu